SCHEDULE: Millennium Entities Disclose 5.5% Stake in Unicycive Therapeutics

Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander have jointly reported beneficial ownership of 5.5% of Unicycive Therapeutics, Inc.'s common stock.

Summary

• Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander collectively beneficially own 1,172,667 shares of Unicycive Therapeutics, Inc. common stock.
• This aggregate amount represents 5.5% of the class of securities.
• The reporting persons hold shared voting power and shared dispositive power over all 1,172,667 shares.
• The filing was made under Rule 13d-1(b), indicating that the securities were not acquired for the purpose of changing or influencing control of the issuer.
• Integrated Core Strategies (US) LLC, Millennium Management LLC, and Millennium Group Management LLC are organized in Delaware, while Israel A. Englander is a U.S. citizen.
• The event requiring this filing occurred on January 16, 2026.

Sentiment

Score: 5

Explanation: This is a routine disclosure of beneficial ownership by institutional investors and does not inherently convey positive or negative sentiment regarding the issuer's performance or prospects.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding Unicycive Therapeutics, Inc.'s future performance or operations.

Management Comments

• Gil Raviv, Global General Counsel, signed on behalf of Integrated Core Strategies (US) LLC, Millennium Management LLC, and Millennium Group Management LLC.
• Israel A. Englander signed on his own behalf.

Industry Context

This filing is a standard disclosure of beneficial ownership by institutional investors, indicating a significant but passive stake in Unicycive Therapeutics. It reflects a portfolio allocation decision by Millennium Management and its affiliates, rather than a strategic industry move or a change in the competitive landscape.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake may be viewed as a vote of confidence by some investors, though the passive nature of the filing (Rule 13d-1(b)) indicates no intent to influence management or control.

Key Dates

Keywords

Unicycive Therapeutics, Millennium Management, Integrated Core Strategies, Israel A. Englander, Beneficial Ownership, Schedule 13G, Common Stock, Institutional Investor